Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pulmonary sarcoidosis.

Robert P Baughman1

  • 1University of Cincinnati Medical Center, 1001 Holmes, Eden Avenue, Cincinnati, OH 45267-0565, USA. bob.baughman@uc.edu

Clinics in Chest Medicine
|August 28, 2004
PubMed
Summary
This summary is machine-generated.

Pulmonary sarcoidosis, a common idiopathic interstitial lung disease, often requires treatment. New therapies beyond corticosteroids are emerging for chronic cases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bridging the Gap: The Emerging Role of memory CD8+ T Cells in Fibrotic Interstitial Lung Disease.

American journal of respiratory cell and molecular biology·2026
Same author

Prevalence of relapse in pulmonary sarcoidosis: A systematic review and meta-analysis.

Respiratory medicine·2026
Same author

Safety and efficacy of namilumab for the treatment of chronic pulmonary sarcoidosis (RESOLVE-Lung): A randomized, double-blinded, multicenter, Phase 2 study.

The European respiratory journal·2026
Same author

Incidence of New Comorbidities After Steroid Use in Patients With Sarcoidosis: An International Cross-Sectional Survey.

Chest·2025
Same author

A paradigm shift in corticosteroid therapy for sarcoidosis: a World Association of Sarcoidosis and Other Granulomatous Disorders Position Paper, endorsed by the Americas Association of Sarcoidosis and Other Granulomatous Disorders.

The Lancet. Respiratory medicine·2025
Same author

WASOG Clinical Trial Endpoint Task Force: Executive Summary.

Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG·2025

Area of Science:

  • Pulmonology
  • Rheumatology
  • Immunology

Background:

  • Pulmonary sarcoidosis is a frequent cause of idiopathic interstitial lung disease.
  • Symptoms vary widely, from asymptomatic cases to severe respiratory failure.
  • While some patients do not need treatment, many require intervention for symptomatic disease.

Purpose of the Study:

  • To review the current treatment landscape for pulmonary sarcoidosis.
  • To highlight the role of corticosteroids in managing the condition.
  • To discuss emerging alternative therapies for chronic pulmonary sarcoidosis.

Main Methods:

  • Literature review of clinical presentations and treatment options for pulmonary sarcoidosis.
  • Analysis of the efficacy and safety of corticosteroids.

Related Experiment Videos

  • Exploration of recent advancements in alternative therapeutic strategies.

    • Main Results:

    • Corticosteroids remain a primary treatment for symptomatic pulmonary sarcoidosis.
    • Alternative therapies have been developed, particularly for chronic or refractory cases.
    • The development of new treatments offers hope for patients with long-term disease.

    Conclusions:

    • Pulmonary sarcoidosis management requires individualized therapeutic approaches.
    • Corticosteroids are effective but associated with potential side effects.
    • Emerging alternative treatments provide valuable options for patients with chronic pulmonary sarcoidosis, improving long-term outcomes.